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Abstract: Articular cartilage lesions that do not disrupt the integrity of subchondral bone are not capable of spontaneous 
repair. The asymptomatic nature of these lesions leads to articular cartilage degeneration and development of the os-
teoarthritic process. To avoid joint replacement surgery, several cellular therapies have been developed. These therapies 
focus on the regeneration of a new tissue, whose structure, biochemistry composition and function should be the same as 
those of endogenous articular cartilage. 
Current approaches for interrupting the osteoarthritic process produce a fibrocartilaginous tissue, not articular cartilage. 
The implantation of autologous chondrocytes and autologous mosaicplasty induces a better quality of articular cartilage; 
however, both techniques damage the existing cartilage because of the need to harvest large numbers of chondrocytes or 
to extract an osteochondral cylinder for implantation. While stem cells are a promising tool for repairing articular carti-
lage, their use is in an early experimental stage at this time. Although studies of cell therapy have shown clinical and func-
tional improvement in joints, the ability to regenerate articular cartilage that resists the degeneration process remains elu-
sive. 
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INTRODUCTION  
 Articular cartilage, which is aneural and relatively avas-
cular, receives its nourishment through diffusion from the 
synovial fluid. The capacity for the self-repair of articular 
cartilage is limited. Modalities of cellular therapy to repair 
focal articular cartilage defects include the implantation of 
cells with chondrogenic capacity and creating access to the 
bone-marrow. The overall objective is not only to heal the 
chondral defect (repair), but to generate new tissue identical 
to native articular cartilage in structure, biochemical compo-
sition and functional behaviour (regeneration). This review 
summarizes the options for treatment of articular cartilage 
defects from both the experimental and clinical perspective 
(Fig. 1). 
PERFORATION OF THE SUBCHONDRAL BONE 
 When the defect affecting the cartilage penetrates to the 
bone and bone marrow spaces (osteochondral injury), mes-
enchymal cells from the bone marrow migrate with the hem-
orrhage and remain in the blood clot filling the defect, and 
are thus responsible for the repair of the defect (Fig. 2) [1]. 
Because this repair is limited to the size of the defect, no 
capacity exists for the spontaneous repair of larger osteo-
chondral injuries. The opening of subchondral vascular  
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spaces is utilized for several surgical strategies, such as ar-
throscopic abrasion [2], subchondral drilling [3], spongiali-
zation [4] and microfracture (which produces the best re-
sults) [5].  
 Experimental studies in rabbits [6, 7] and dogs [8] have 
shown that the repair tissue generated by these processes is 
fibrocartilaginous in nature, differing from hyaline articular 
cartilage in biochemical composition, structural organiza-
tion, durability and biomechanical properties, and degener-
ates over time [1, 7]. The co-expression of types I and II col-
lagens in repair tissue does not occur until one year follow-
ing subchondral penetration [9]. Clinical results, to some 
degree, contradict the findings relating to the quality of the 
repair tissue. For example, the treatment of knee osteochon-
dral defects by microfracture has provided good clinical re-
sults after two years [10]. This longevity, however, seems to 
be age-dependent, with the most persistent repair cartilage in 
patients under the age of 40 [11]. Although the initiation of a 
degenerative process for tissue repair has been described at 
18 months after microfracture [12], and seven to 17 years 
after microfracture, improvement in articular function and 
pain relief were preserved [13].  
IMPLANTS OF PERIOSTIUM AND PERICHON-
DRIUM 
 These membranes contain mesenchymal stem cells that 
are capable of chondrogenesis [14, 15]. The periostial or 
perichondrial implant forms a fibrocartilaginous repair tissue 
that does not seem to mature over time [16, 17]. However,  
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the clinical effects of a perichondrium implant are similar 
those of subchondral perforation. At 10 years following ei-
ther procedure there were no significant differences observed 















Fig. (2). Types of defects of articular cartilage. A). Partial defect. 
The lesion includes cartilage tissue and part of the subchondral 
bone. B). Deep defect. Subchondral bone is perforated to the bone 
marrow. c: cartilage; cc: calcified cartilage; sb: subchondral bone; 
bm: bone marrow. 
OSTEOPERIOSTEAL IMPLANTS 
 Osteoperiosteal plug transplantation (bone plugs with a 
covering periosteal layer) into a mosaicplasty donor-site de-
fect produces new fibrous tissue in animal models [19] that 
can acquire fibrocartilaginous characteristics by use of chon-
drogenic inductors [20]. Bleeding from bone marrow spaces 
from the injury probably interferes with the repair action of 
the periostium germ layer. In rabbits, nearly 67% of repair 
tissue cells was derived from the bone marrow after osteope-
riosteal implantation [21]. Although this repair tissue appears 
to be of low histological quality, improved articular function 
and pain relief have been observed following this procedure 
[22]. 
MOSAICPLASTY 
 Autologous mosaicplasty is considered to be a promising 
alternative for treatment of small to medium-sized focal 
chondral and osteochondral defects [23]. This technique in-
volves the translocation of osteochondral cylinders, or plugs, 
from a low-weight-bearing normal site to a high-weight-
bearing diseased site. The donor sites spontaneously repair 
with mesenchymal stromal cells from the bone marrow to 
promote a new fibrocartilaginous tissue.  
 Arthroscopic evaluations at five [24] and 10 years [25] 
after osteochondral cylinder implantation showed survival of 
the transplanted articular cartilage, congruency between op-
posing (treated and untreated) joint surfaces and fibrocarti-
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chondral cylinders protrude above the surface, joint prob-
lems can arise. At four months post-surgery, patients with 
protruding cylinders experienced a “catching sensation” and 
some of these patients reported joint pain. Arthroscopic ex-
aminations of these cases revealed fissures in the osteochon-
dral cylinders and fibrillation around the recipient site [26]. 
 The use of autologous mosaicplasty is limited by the de-
fect size, which determines the number of osteochondral 
cylinders required. The articular cartilage produced by this 
technique exhibits topographical variations in morphologi-
cal, biochemical and physical properties [27, 28]. Because 
the implanted tissue is harvested from a low-weight-bearing 
area, the cartilage is thinner and differs in histological struc-
ture from cartilage from high weight-bearing areas [29, 30].  
OSTEOARTICULAR ALLOTRANSPLANTATION 
 The use of osteoarticular allotransplantation may address 
some of the limitations of mosaicplasty where injury to the 
low-weight-bearing area of the cartilage is avoided, particu-
larly if a large number of osteochondral cylinders are re-
quired. The advantage of the shell allograft is that it is ob-
tained from a donor site that matches the precise location of 
the recipient and thereby in more likely to have a similar 
architecture. Furthermore, immunological problems are rare 
due to the avascular nature of cartilage and the encapsulation 
of chondrocytes in the extracellular matrix. In practice, shell 
osteochondral allotransplant in the knee is well integrated 
and provides a consistent functional improvement and pain 
relief after two years [31]. Graft requiring larger portions of 
bone for traumatic defects also do well. After 10 years, 85% 
of the implants proved durable [32]. 
AUTOLOGOUS CHONDROCYTE IMPLANTATION 
 A therapeutic alternative offering more effective repair of 
focal articular cartilage defects is autologous chondrocyte 
implantation (ACI) [33-36]. This procedure is also used for 
patients with osteochondritis dissecans [37], but not for os-
teoarthritis joints. Because the results of this technique are 
highly age-dependent, the use of this procedure is recom-
mended for patients younger than 55 years of age. The tech-
nique involves obtaining, by arthroscopy, articular cartilage 
explants from low-weight-bearing areas (Fig. 3). Chondro-
cytes are then isolated and grown in vitro to obtain a suffi-
cient number of cells for implantation. In a second surgical 
intervention, the cultured chondrocytes are injected into the 
defect cavity, which is then closed with periosteal membrane 
from the same patient. 
 Autologous chondrocyte implantation has several short-
comings: a) obtaining cartilage explants requires an addi-
tional surgical intervention, adding to the articular cartilage 
damage that increases the osteoarthritic process; b) in vitro 
chondrocyte proliferation must be limited because the capac-
ity to produce stable cartilage in vivo is gradually reduced 
when cell divisions are increased [38]; c) aging reduces the 
cellular density of the cartilage, which impacts chondrocyte 
proliferation capacity in vitro [39] and the chondrogenic po-
tential of the periostium [40], and d) cell culture procedures 
take too long (three to six weeks) and increase the risk of 
contamination.  
 The first article about ACI in humans appeared in 1994 
[33]. Clinical and arthroscopic evaluations of femoral im-
plants showed good results after two years. Early studies 
demonstrated the durability of the implant, with good clini-
cal results observed at five to 11 years post-procedure [37]. 
Histological analysis of the de novo formed tissue revealed 
some heterogeneity in the quality of the repair tissue. Of the 
41 biopsies obtained one year following implantation, 10% 
consisted of hyaline cartilage; 24% consisted of a mixture of 
hyaline cartilage and fibrocartilage; 61% were entirely fibro-
cartilage and 5% consisted only of fibrous tissue [41]. 
 Other studies at one year after implantation have shown 
that fibrocartilaginous morphology regions and hyaline mor-
phology regions coexist in the same biopsy; both types hav-
ing proteoglycans and type II collagen [34, 36]. Furthermore, 
aggrecanase activity was higher than metalloprotease activi-
ties in the fibrocartilaginous regions although both enzymes 
were found [36]. The expression of type IIA and IIB colla-
gen mRNA was also detected [42]. These mRNA expres-
sions seem be characteristic of the prechondrocytic state 
(type IIA) and differentiated chondrocytes (type IIB) [43]. 
These results suggest that ACI induces the regeneration of 
articular cartilage, probably by the turnover and remodeling 
from an initial fibrocartilaginous matrix using enzymatic 
degradation and synthesis of type II collagen [36]. It is be-
lieved that this process continues for more than 24 months 
following the implantation [35, 44] and takes place in three 
specific stages: cell proliferation (the first six weeks), transi-
tion (seven to 26 weeks) and remodeling (beyond 27 weeks) 
[45]. 
 Doubt has been cast upon the use of periosteal mem-
branes for retaining the chondrocyte suspension because the 
procedure requires a large surgical incision and can lead to 
peripheral graft hypertrophy and potential ectopic calcifica-
tion. To obviate this problem, the use of a type I/III collagen 
patch has been proposed [46-48]. Any differences between 
the results of using periostium or the collagen patch remain 
controversial. A comparative study of these two techniques 
at two years post-operative has revealed no statistically sig-
nificant differences between the clinical outcomes of ACI 
with collagen membranes versus ACI with periostium. How-
ever, a substantial number of patients who had ACI with 
periostium required subsequent shaving of an hypertrophied 
graft [48].  
 Matrix-associated autologous chondrocyte implantation 
(MACI) is another procedure that uses a cell-seeded collagen 
matrix for treatment of cartilage defects. A prospective clini-
cal investigation carried out in 38 patients with localized 
cartilage defects for a period of up to five years after surgery, 
showed that MACI represents a viable alternative for treat-
ment of local cartilage defects of the knee [49]. 
ALLOTRANSPLANTATION AND XENOTRANS-
PLANTATION OF CHONDROCYTES 
 Other therapeutic alternatives include allotransplantation 
[50-52] and xenotransplantation of chondrocytes [53, 54]. 
Allotransplantation is constrained by the necessity for com-
patible donors and limitations on storage of cartilage or 
chondrocytes because cryopreservation reduces survival and 
proliferation of chondrocytes. Xenotransplantation may re-
solve some of these problems, but this therapeutic alternative 
has rarely been investigated. The immune barrier is an im-
portant objection to the use of both of these procedures. Iso-
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lated chondrocytes result in immunogenic reaction, but allo-
implantation of chondrocytes encapsulated in their extracel-
lular matrix [52] or embedded in collagen gel or agarose [50, 
51] resulted in few or no rejection reactions. Notably, xeno- 
transplantation in vivo of cultured pig chondrocytes into rab-
bit chondral defects closed with periosteal membrane no 
signs of infiltration by immune cells [54].  
MESENCHYMAL STEM CELLS TRANSPLANTA-
TION 
 Mesenchymal stem cells (MSCs) can differentiate in vi-
tro into a number of cell types, including adipocytes, chon-
drocytes and osteoblasts [55]. This procedure uses cells iso-
lated from small tissue samples, proliferated in culture, to 
obtain the appropriate number for clinical applications. They 
can be implanted in the donor patient, obviating rejection 
problems. Mesenchymal stem cells may be a tool for tissue 
repair that has the advantage of avoiding the problem of im-
munological rejection of the allotransplant and the ethical 
conflict of using embryonic stem cells. 
 MSCs are wide distributed in vivo, being found in bone 
marrow [56], periostium [57], perichondrium [58], synovial 
membrane [59], connective tissue of dermis and skeletal 

























Fig. (3). Implant of autologous chondrocytes. A and B: biopsy. C and D: chondrocytes are obtained by by enzymatic digestion (trypsin and 
type IV collagenase). E: cells proliferate in a culture flask at 37°C. F: femoral condyle with chondral lesion. G: The defect cavity is closed 
with a patch (periosteum, type I/III collagen), then the chondrocyte suspension is injected. 
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peripheral blood [63, 64], amniotic membrane [65] and even 
in articular cartilage [66]. Although bone marrow is the usual 
source of MSCs, umbilical cord blood is emerging as an im-
portant reservoir for stem cells capable of differentiation into 
many cell types and possessing the advantages of immune 
status and relatively unshortened telomere length [67]. 
 Because there is no specific marker for MSCs, the prin-
cipal criteria for identification are adherence to the plastic of 
the tissue culture flask, fibroblast-like morphology [68], the 
prolonged capacity for proliferation in supportive media and 
the capacity to differentiate in vitro into cells of mesodermal 
origin (chondrocytes, adipocytes, osteoblasts). Furthermore, 
characteristics of MSCs are the absence of expression of 
typical hematopoietic antigens like CD34 and CD45, and the 
expression of surface markers like Stro-1, CD44, CD73, 
CD90, CD105 y CD166 [69]. 
 The low number of MSCs isolated from a tissue sample 
requires growth in vitro. However, the number of mitotic 
divisions of MSCs in culture must be limited because MSCs 
age during in vitro culture, causing a reduction in their pro-
liferative capacity [70, 71] and gradual loss of the potential 
for multiple differentiation [70, 72]. The conservation of phe- 
notype and differentiation capacity of MSCs are proportional 
to telomerization [73]. Telomeres are normally shortened in 
successive cell divisions, however, in embryonic stem cells 
the telomere length is restored by telomerase enzyme activ-
ity. On the other hand, MSCs lack [74] adequate levels of 
telomerase activity to achieve telomeric restoration [72, 75, 
76]. Patient age also influences the characteristics of MSCs 
because their proliferative capacity is reduced by aging [77]. 
 Several studies have indicated that the MSC population 
obtained from a tissue sample contains cell subsets with dis-
tinct differentiation stages. Furthermore, MSCs from differ-
ent tissue sources can have biologic distinctions. For exam-
ple, MSCs derived from bone marrow show a higher poten-
tial for osteogenic differentiation [78], while MSCs of syno-
vial origin show a greater tendency toward chondrogenic 
differentiation [79]. Under identical culture conditions for 
differentiation, MSCs isolated from the synovial membrane 
show more chondrogenic potential than those derived from 
bone marrow, periostium, skeletal muscle or adipose tissue 
[80]. 
 Studies of cartilage injury repair in animal models using 
MSCs embedded in collagen gel [50] or injected into defects 
closed with periosteal membrane [81] indicate that MSCs 
can differentiate in vivo into a number of cell types in differ-
ent biologic environments.  
 Several studies have recently reported the migration of 
intraarticularly injected MSCs to the site of a cartilage injury 
to repair chondral defects. In a caprine model for osteoarthri-
tis in which OA is induced by the complete excision of the 
medial meniscus and resection of the anterior cruciate liga-
ment, the intraarticular injection of MSCs produced menis-
cus repair after six weeks; however, there was no evidence of 
cartilage or ligament repair [82]. This suggests that the in-
jected MSCs migrated to the injured meniscus, but not the 
damaged cartilage. The intraarticular injection of MSCs into 
rat knees, however, showed mobilization of these cells to-
wards all injured tissues, including articular cartilage; the 
MSCs contributed to tissue regeneration [83, 84].  
 Studies of treatment with MSCs for human chondral le-
sions are rare. In osteoarthritic knees, MSCs embedded in 
collagen gel were implanted into chondral defects and closed 
with periosteal membrane. After 42 weeks, arthroscopic and 
histological results were better than in osteoarthritic patients 
without implants, although there was no statistically signifi-
cant improvement in clinical results [85]. The use of MSCs 
to treat chondral lesions clinically has not been established, 
in part because the stages of chondrogenic differentiation of 
MSCs are not sufficiently defined. In addition, there are cur-
rently no protocols that ensure direct differentiation to the 
desired phenotype; the plasticity of the cells differentiated 
from MSCs can lead to undesirable phenotypic alterations 
[86, 87].  
SCAFFOLDS 
 Scaffold-guided tissue regeneration involves differenti-
ated or mesenchymal stem cells, scaffolds and bio-active 
factors. Requirements for the biomaterials used as a scaffold 
include biocompatibility, suitable ligands for implanted cell 
attachment, integration with native cartilage and biodegrada-
tion into non-toxic products that can be replaced by host 
cells. Other important factors in the design of a scaffold are 
pore size, porosity, adaptive shape, mechanical integrity, the 
ability to be retained at the implantation site and cost effi-
ciency. 
 Natural biomaterials, such as fibrin, collagen, agarose, 
alginate, hyaluronic acid or chitosan [88-92] and synthetic 
biomaterials, such as poly-lactic glycolic acid (PLGA) [93] 
and a polymeric nanofiber [94], are used alone or in different 
combinations to make scaffolds.  
 Mechanical and biological properties of biomaterials 
significantly influence chondrogenesis and the long-term 
maintenance of the structural integrity of the neo-formed 
tissue. The three-dimensional nature of the scaffolds pro-
motes maintenance of a rounded cell morphology and the 
elevated expression of glycosaminoglycans and type II col-
lagen [92, 95]. However, scaffolding biomaterials have dif-
fering influences on the metabolism of host cells and, conse-
quently, the quality of the tissue-engineered cartilage [90, 
96]. For example, the use of chitosan, compared to PLGA, 
for cartilage tissue engineering produces a superior mainte-
nance of structural integrity because the expression of type II 
collagen protein and mRNA became weaker over time in the 
PLGA group [96]. Scaffolds using hyaluronic acid are also 
being used with excellent clinical and histological results 
[97]. 
GENE THERAPY 
 The introduction of genetic manipulations into the field 
of tissue damage repair can enhance the process of articular 
cartilage restoration. This process involves the determination 
of the appropriate gene and type of cell (chondrocytes, chon-
drogenic cells and cells of the synovial membrane) for the 
gene transference, as well as the determination of the optimal 
vector to incorporate the cDNA [98]. Several anabolic fac-
tors [members of the transforming growth factor-  (TGF- ) 
super-family, insulin-like growth factor-1 (IGF-1), fibroblast 
growth factor (FGF) and hepatocyte growth factor (HGF) 
induce chondrogenesis and synthesis of extracellular mem-
brane components. Anti-inflammatory molecules, such as 
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interleukin-4 (IL-4), IL-10, IL-1 receptor antagonist (IL-
1Ra), and tumor necrosis factor soluble receptor (TNFsR) 
act as inhibitors to articular cartilage degradation [99]. 
 The synovial membrane seems useful as a target for 
chondroprotective therapies [100]. The viral transfection in 
vivo with the IL-1Ra gene in rheumatoid arthritis joints re-
duces the severity of the disease process in animal models 
[101]. Furthermore, this technique makes possible the safe 
intraarticular expression of the IL-1Ra gene [102, 103]. 
Chondrocytes and MSCs are the preferred targets for the 
induction of chondrogenesis. Using animal models, the 
transplantation in vivo of MSCs transfected with bone mor- 
phogenetic protein-2 (BMP-2) cDNA produces improved 
chondral lesion repair with a higher production of proteogly-
cans and type II collagen compared to controls [104]. 
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